The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
cDC1 prime and are licensed by CD4(+) T cells to induce anti-tumour immunity
Open accessAbstract
Conventional type 1 dendritic cells (cDC1)1 are thought to perform antigen cross-presentation, which is required to prime CD8+ T cells 2,3, whereas cDC2 are specialized for priming CD4+ T cells 4,5. CD4+ T cells are also considered to help CD8+ T cell responses through a variety of mechanisms 6-11, including a process whereby CD4+ T cells 'license' cDC1 for CD8+ T cell priming 12. However, this model has not been directly tested in vivo or in the setting of help-dependent tumour rejection. Here we generated an Xcr1 Cre mouse strain to evaluate the cellular interactions that mediate tumour rejection in a model requiring CD4+ and CD8+ T cells. As expected, tumour rejection required cDC1 and CD8+ T cell priming required the expression of major histocompatibility class I molecules by cDC1. Unexpectedly, early priming of CD4+ T cells against tumour-derived antigens also required cDC1, and this was not simply because they transport antigens to lymph nodes for processing by cDC2, as selective deletion of major histocompatibility class II molecules in cDC1 also prevented early CD4+ T cell priming. Furthermore, deletion of either major histocompatibility class II or CD40 in cDC1 impaired tumour rejection, consistent with a role for cognate CD4+ T cell interactions and CD40 signalling in cDC1 licensing. Finally, CD40 signalling in cDC1 was critical not only for CD8+ T cell priming, but also for initial CD4+ T cell activation. Thus, in the setting of tumour-derived antigens, cDC1 function as an autonomous platform capable of antigen processing and priming for both CD4+ and CD8+ T cells and of the direct orchestration of their cross-talk that is required for optimal anti-tumour immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“cDC1 are critical for antigen cross-presentation required to prime CD8+ T cells for optimal anti-tumor immunity and priming of CD4+ T cells at early stages, partly because cDC1 provides antigen transportation to lymph nodes for processing by cDC2 (36).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [36]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CD40 signaling in cDC1 is required for tumor rejection by playing a key role in augmenting the proliferation of antigen-specific CD8+ T cells (36).”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus
Srinivas, S., Watanabe, T., Lin, C.-S., William, C. M., Tanabe, Y., Jessell, T. M., & Costantini, F. (2001) · BMC Developmental Biology · doi:10.1186/1471-213x-1-4 · Cited by 3,121
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
Ridge, J. P., Rosa, F. D., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,360
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
Bennett, S. R. M., Carbone, F., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,091
Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081
Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny
Guilliams, M., Ginhoux, F., Jakubzick, C., Naik, S. H., Onai, N., Schraml, B. U., Segura, É., Tussiwand, R., & Yona, S. (2014) · Nature reviews. Immunology · doi:10.1038/nri3712 · Cited by 1,923
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,454
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. J., Arthur, C. D., White, J. M., Chen, Y.-S., Shea, L. K., et al. (2012) · Nature · doi:10.1038/nature10755 · Cited by 1,285
Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help
Sun, J. C., & Bevan, M. J. (2003) · Science · doi:10.1126/science.1083317 · Cited by 1,213
Cited by
Sorted by citations
Items 401–500 of 615
Surnov, A., & Hawiger, D. (2021) · Oncotarget · doi:10.18632/oncotarget.27967 · Cited by 4
Agonistic anti-CD40 converts Tregs into Type 1 effectors within the tumor micro-environmentPreprint
Maltez, V. I., Arora, C., Sor, R., Lian, Q., Vonderheide, R. H., Germain, R. N., & Byrne, K. T. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.17.512537 · Cited by 3
Srinivasan, J., Moore, C. R., Calindi, A., Helm, B. R., Yang, Y., Moore, J. F., Selden, H. J., Heiser, C. N., Liu, Q., Lau, K. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.18.572281 · Cited by 4
Zhao, Q., Xiao, M., Ma, J., Fu, C., Gao, Q., & Bi, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1465664 · Cited by 3
Immune-checkpoint inhibitor resistance in patients with cancer
Cabezón‐Gutiérrez, L., Custodio‐Cabello, S., Palka-Kotlowska, M., Chacón-Ovejero, B., & Pacheco-Barcía, V. (2025) · Exploration of Immunology · doi:10.37349/ei.2025.1003196 · Cited by 4
Sun, Y., Nakanishi, H., Huang, X., Ma, G., Gao, X., & Xia, Y. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123690 · Cited by 3
Wang, M., Ran, C., & Liu, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1674174 · Cited by 3
T H 1 effector CD4 T cells rely on IFN-γ production to induce alopecia areata
Connell, S. J., Crotts, S. B., Reis, R. J., Lensing, M., Kahl, P., Henderson, N., Ayush, O., Zhu, Z., Ortolan, L. D. S., Ko, A. C., et al. (2025) · Science Advances · doi:10.1126/sciadv.adz2257 · Cited by 3
Elias‐Oliveira, J., Rodrigues, V. F., Pereira, Í. S., Barbosa, S. C., Pereira, J. A., Pacheco, T. C. F., Machado, M. S. G., Masson, A. P., Rios, W. M., Gardinassi, L. G., et al. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05928-x · Cited by 3
Advances in the development of personalized neoantigen therapies
Brightman, S. E., & Butterfield, L. H. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20241234 · Cited by 5
Soyano, A. E., Lee, M. C., Han, H. S., Aldrich, A. L., Soliman, H., Olson-Mcpeek, S. K., Balsay-Patel, C., Aiello, P. M., Farrell, C. M., Weinfurtner, R. J., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013590 · Cited by 3
Integrative CSF profiling identifies disease-specific immune responses in leptomeningeal disease
Nieto, P., Klinsing, S., Caratù, G., Dettki, M., Marchese, D., Weber, K. J., Morabito, S., Lorden, P., Ruano, I., Imkeller, K., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102651 · Cited by 3
Maltez, V. I., Arora, C., Gribbin, K. P., Caruso, B. P., Haerr, M. E., Sor, R., Lian, Q., Blise, K. E., Sivagnanam, S., Sears, R. C., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.03.011 · Cited by 3
CD4 + T cells impair tumor growth through IL-3 and TNF-dependent vascular damage
Lian, Q., Nie, J., Singh, J., Chen, Q., Matta, J. L., Chan, W., Balmaceno-Criss, M., Vacchio, M. S., Yu, W., Clark, A. D., et al. (2026) · Science · doi:10.1126/science.ads7910 · Cited by 5
Koufaki, M. A., Richardson, E., Bonavita, E., Reeves, R., Moeini, A., Chiang, S., Banyard, A., Russo, M., Earnshaw, C. H., Bell, C. R., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.07.002 · Cited by 5
Origin, Phenotype, and Function of Mouse Dendritic Cell Subsets
Duluc, D., & Sisirak, V. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-2938-3_1 · Cited by 3
Ready for Prime Time? Dendritic Cells in High-Grade Gliomas
Conarroe, C. A., & Bullock, T. N. J. (2023) · Cancers · doi:10.3390/cancers15112902 · Cited by 3
Lamens, K. D., Lan, J., Eddens, T. J., Rogers, M. C., Tometich, J. T., Hand, T. W., & Williams, J. V. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf076 · Cited by 3
Boosting Dendritic Cell Function in Cancer
Giampazolias, E. (2025) · Cancer Medicine · doi:10.1002/cam4.71062 · Cited by 3
CD4+ T Cells Mediate MHC-Deficient Tumor Rejection and Endothelial Cell Reprogramming
Kim, S. I., Haerr, M. E., Al-Ghezi, M., Chen, C., Zhang, Y., Phipps, J. L., Arora, C., Gribbin, K. P., Kim, G. T., Markosyan, N., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1342 · Cited by 3
Vps33B in Dendritic Cells Regulates House Dust Mite–Induced Allergic Lung Inflammation
Ma, J., Han, M., Yang, D., Zheng, T., Hu, R., Wang, B., Ye, Y., Liu, J., & Huang, G. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100502 · Cited by 3
A novel ZsGreen knock‐in melanoma cell line reveals the function of CD11b in tumor phagocytosis
Zhang, L., Feng, X., Shen, Y., Wang, Y., Liu, Z., Ma, Y., Gu, Y., Guo, G., Duan, L., Lu, L., et al. (2022) · Immunology and Cell Biology · doi:10.1111/imcb.12575 · Cited by 3
Matsuba, S., Ura, H., Saito, F., Ogasawara, C., Shimodaira, S., Niida, Y., & Onai, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264609 · Cited by 3
Vaccine a promising immunotherapy option for head and neck cancer patients
Mohsin, S. F. (2024) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.40.7.8791 · Cited by 3
Mahadevan, K. K., Dyevoich, A. M., Chen, Y., Li, B., Sugimoto, H., Sockwell, A. M., McAndrews, K. M., Wang, H., Shalapour, S., Watowich, S. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.05.531191 · Cited by 3
Lorrey, S., Wachsmuth, L. P., Finlay, J. B., Neff, C., Ayasoufi, K., Polania, J. W., Hoyt-Miggelbrink, A. M., Price, M., Rein, L. A. M., Dell, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.02.565368 · Cited by 3
Keshari, S., Shavkunov, A. S., Miao, Q., Saha, A., Williams, C. D., Highsmith, A. M., Pineda, J. E., Alspach, E., Hu, K. H., Pauken, K. E., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4755484 · Cited by 3
Chaib, M., Aminu, M., Herbrich, S. M., Arabi, M., Xuan, Y., Basi, A., Casasent, T. D., Macaluso, M. D., Hu, K. H., Gubin, M. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.24.696419 · Cited by 3
Adaptive-like CAR-iPSC-CD4⁺ T cells outperform CD8⁺ counterparts in sustained ALL control
Guo, Q., Zhang, C., Wang, B., Iriguchi, S., Ishikawa, A., Minagawa, A., Ishii, T., Kawai, Y., & Kaneko, S. (2026) · Inflammation and Regeneration · doi:10.1186/s41232-025-00402-4 · Cited by 3
Rong, X., Wang, H., Muraoka, S., Uehata, T., Yoshinaga, M., Kaisho, T., & Takeuchi, O. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1725702 · Cited by 3
PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC
Shao, Z., Liu, Q., Xin, Z., Zhou, Z., Lin, M., Chen, D., Hao, Z., Chen, Y., Wu, W., Zhang, S., et al. (2026) · Advanced Science · doi:10.1002/advs.202507647 · Cited by 2
Srinivasan, J., Moore, C. R., Calindi, A., Helm, B. R., Yang, Y., Moore, J., Selden, H. J., Heiser, C. N., Liu, Q., Lau, K. S., et al. (2026) · Nature Immunology · doi:10.1038/s41590-025-02371-9 · Cited by 6
Mishra, R., Ademuyiwa, F. O., Yang, Y., Herndon, J. M., Li, L., Street, C., Myers, N. B., Chen, I., Zhang, X., Hagemann, I. S., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-25-0666 · Cited by 2
Rao, X., Onyshchenko, K., Wang, M., Luo, R., Zhang, X., Wang, L., Kuhn, S., Yang, Y., Gaedicke, S., Grosu, P. A.-L., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013055 · Cited by 4
The lethal symbiont: exploring the pathophysiology of cancer
Nolan, E., Li, L., Giampazolias, E., Ombrato, L., & Malanchi, I. (2026) · Physiological Reviews · doi:10.1152/physrev.00019.2025 · Cited by 2
Busselaar, J., Bosma, D. M. T., Staal, M. D., Lei, X., Xiao, Y., & Borst, J. G. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014041 · Cited by 4
Nanobiotechnology for dendritic cell-based cancer immunotherapy
Li, R. H., Yi, W., Qian, X., Hu, S., Shen, H., Yan, D., & Li, Y. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100485 · Cited by 2
Pi, Y., Li, Y.-F., Liang, R., Jian, X., Leng, J., & Zhang, L. (2022) · Central European Journal of Immunology · doi:10.5114/ceji.2022.117767 · Cited by 2
In Vitro and In Vivo Assays to Evaluate Dendritic Cell Phagocytic Capacity
Maisonneuve, L., & Manoury, B. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-2938-3_20 · Cited by 2
Noe, P., Wang, J. H., Chung, K., Cheng, Z., Field, J. J., Shen, X., Casey, S. C., Cortesio, C. L., Pastuskovas, C. V., Phee, H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1272055 · Cited by 2
Huang, S., Lai, Y., Liao, H.-T., Chang, C.-L., Ma, R.-Y., Chen, Y., Liou, Y.-H., Wu, Z., Wu, Y.-C., Liu, K., et al. (2025) · eLife · doi:10.7554/elife.99010.3 · Cited by 2
Huang, L., Liu, Y., Shi, Y., Sun, Q., Li, H., & Sun, C. (2025) · Discover Oncology · doi:10.1007/s12672-025-01929-1 · Cited by 2
Rappaport, A., Bekerman, E., Boucher, G. R., Sung, J., Carr, B., Corzo, C. A., Larson, H., Kachura, M. A., Scallan, C. D., Geleziunas, R., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkae052 · Cited by 3
Yao, Y., Zhang, Z., Wang, S., Wang, J., Hao, Y., Wang, K., & Liu, P. (2025) · Cells · doi:10.3390/cells14080620 · Cited by 2
Fungal immunization potentiates CD4+ T cell-independent cDC2 responses for cross-presentation
Kulkarni, N. A., & Nanjappa, S. G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1602174 · Cited by 2
The role of dendritic cells in recurrent pregnancy loss
Yuan, X., Li, C., Yang, L., Zhang, X., & Feng, X. (2025) · Immunologic Research · doi:10.1007/s12026-025-09664-z · Cited by 2
Tam, H., Shen, H., Xu, Y., An, J., & Cyster, J. G. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20250887 · Cited by 2
Leavenworth, J. W., Liu, X., Ma, Y., Zhu, Y., & Qi, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1023967 · Cited by 2
Victora, G. D., Chudnovskiy, A., Nakandakari-Higa, S., Castro, T. B. R., Cui, A., Lin, C., Sade-Feldman, M., Phillips, B. K., Pae, J., Mesin, L., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2152423/v1 · Cited by 2
Engineered probiotics limit CNS autoimmunity by stabilizing HIF-1α in dendritic cellsPreprint
Sanmarco, L., Rone, J. M., Polonio, C., Giovannoni, F., Lahore, G. F., Ferrara, K., Gutiérrez-Vázquez, C., Li, N., Sokolovska, A., Plasencia, A., et al. (2023) · bioRxiv · doi:10.1101/2023.03.17.532101
Cohn, I. S., Wallbank, B. A., Haskins, B. E., O’Dea, K. M., Pardy, R. D., Shaw, S., Merolle, M. I., Gullicksrud, J. A., Christian, D. A., Striepen, B., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.11.566669 · Cited by 2
Chakraborty, A. K., Kroehling, L., Raut, R. D., Choudhury, C., Kukuruzinska, M. A., Gutkind, J. S., Varelas, X., Sahay, B., Monti, S., & Bais, M. V. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.17.643710 · Cited by 2
Capietto, A.-H., Balança, C.-C., Bouziat, R., Wu, T. D., Gober, J. G., Carbone, C. B., Nissenbaum, A., Hoshyar, R., Yadav, M., Gutierrez, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.09.657934 · Cited by 2
Thymic DC2 are heterogenous and include a novel population of transitional dendritic cellsPreprint
Vobořil, M., Sulczewski, F. B., Martinez, R. J., Ashby, K. M., Valerio, M. M., Idoyaga, J., & Hogquist, K. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.13.659520 · Cited by 2
Antigen-presenting mast cells are new players in breast cancer immunotherapy
Luri‐Rey, C., Teijeira, Á., & Melero, I. (2025) · Nature Medicine · doi:10.1038/s41591-025-03740-5 · Cited by 2
Mayoux, M., Litscher, G., Wiesmann, F., Vermeer, M., Adolff, P. J., Vinzoni, E. G., Núñez, N. G., Sparano, C., Vetter, V. K., Friebel, E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.22.671704 · Cited by 1
Pan-cancer virtual spatial transcriptomics from routine histology with PhoenixPreprint
Tran, M., Gindra, R. H., Putze, P., Senbai, 康. K., Palla, G., Šket, T., Falcomatà, C., Wang, C., Guo, R., Boxberg, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.25.720812 · Cited by 4
A multidimensional analysis and future perspectives of cellular cancer vaccines
Li, X., Song, R., Zhu, J., He, J. B., & Liu, X. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152380 · Cited by 1
From trash to treasure: tumor draining lymph nodes as a multi-omics goldmine in cancer therapy
Li, Y., Chen, Z., Zhikun, G., Yu, J., Lu, J., Wang, L., & Zhou, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1636942 · Cited by 1
Innate immune cells in oral squamous cell carcinoma: Characteristics and therapeutic potential
Jiang, Y., Cheng, J., Wu, J., Liu, O., & Bin, X. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189444 · Cited by 1
Requirements for development of T helper 1 and T follicular helper cells from a common precursor
Bosma, D. M. T., Busselaar, J., Staal, M. D., de Koning, M., Reljić, M., Lei, X., de Wit, T., Xiao, Y., Borst, J. G., & Salerno, F. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117296 · Cited by 1
Siglec-1+ macrophages in anti-tumor immunity
Mauvais, F., & Endert, P. V. (2025) · Immunology Letters · doi:10.1016/j.imlet.2025.107108 · Cited by 1
Wang, T., Hu, H., Feng, G.-H., Su, J., Zhuo, S., Huang, Z., & Li, Y. (2025) · Nano Research · doi:10.26599/nr.2025.94908278 · Cited by 1
Hargadon, K. M. (2026) · Lymphatics · doi:10.3390/lymphatics4010002 · Cited by 1
Schuster, C., Frey, B., Fietkau, R., Corradini, S., Gaipl, U. S., & Derer, A. (2026) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2025.101102 · Cited by 1
Wang, H., Meng, Q., Ito, Y., Kusumakar, K., & Mayadas, T. N. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0509 · Cited by 1
The DC1 conundrum: Do type I dendritic cells make or break allograft tolerance?
Shen, I. R., Jeyamogan, S., Jones, R., Mathew, J. M., Thorp, E. B., & Davidson, J. T. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.02.019 · Cited by 1
An ontogeny-cytokine code determines macrophage response polarity and tumor outcomes
Schaer, D. J., Schulthess-Lutz, N., Peterhans, M., Baselgia, L., Eschment, M., Humar, R., & Vallelian, F. (2026) · Communications Biology · doi:10.1038/s42003-026-09853-y · Cited by 1
Yang, Z., Cao, S., Zhang, J., Nie, X., Wang, Z., Yang, S., Wang, J., Sun, X., Kuang, X., Huang, H., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02664-x · Cited by 2
Kamigaichi, A., Kagamu, H., Miyata, Y., Mimae, T., Tsubokawa, N., HIRANO, K., & Okada, M. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04357-4 · Cited by 1
Neoantigen-based T cell vaccines design strategies, therapeutic barriers, and clinical advances
Shi, J., Wang, J., 罗红梅, Zhao, Q., Yao, Z., Wu, G., Li, Z., Wang, H., Chen, G. D., & Wu, D. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128659 · Cited by 2
Vounckx, M., Dirven, I., Bertels, C., Schwarze, J. K., Geeraerts, X., Tuyaerts, S., Boisson, A., Willard-Gallo, K. E., & Neyns, B. (2026) · Vaccines · doi:10.3390/vaccines14050402 · Cited by 1
Nguyen, T. T., Gómez, H. F., Lütge, M., Yángüez, E., Hüsser, T., Nassiri, S., Trumpfheller, C., Colombetti, S., Deak, L. C., Umaña, P., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014620 · Cited by 1
Cross-priming underlies the efficacy of antibody–drug conjugates and immunotherapy combinations
Gomis, G., Berraondo, P., Herrero, C., Luri‐Rey, C., & Melero, I. (2026) · Trends in Immunology · doi:10.1016/j.it.2026.06.003 · Cited by 1
Wu, J., Fan, J., Sha, T., & Li, H. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08602-3 · Cited by 2
The promising cancer treatment approach in cancer immunotherapy: dendritic cell-based vaccines
Wang, J., Jia, X., Zhang, Y., Wang, X. G., Fu, Y., & He, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1902454 · Cited by 1
The IL-1 system in inflammation and cancer
Garlanda, C., Bonavita, E., Garuti, R., Supino, D., & Scavello, F. (2026) · Seminars in Immunology · doi:10.1016/j.smim.2026.102051 · Cited by 1
Engineered probiotics for tumor-targeted combination chemoimmunotherapy
Yang, Z., Im, J., Chen, N., Mariuzza, D. L., Santos, K. D. L., Li, F., Ballister, E. R., Ringham, O. R., Danino, T., & Arpaia, N. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.ady2289 · Cited by 2
Zeng, X., Zhang, Y., Wu, C., Duan, Q., Fan, M., Wang, K., Cai, S., & Yasa, I. C. (2026) · Advanced Science · doi:10.1002/advs.77760 · Cited by 1
De novo priming: driver of immunotherapy responses or epiphenomenon?
Young, A. L., Lorimer, T., Al-Khalidi, S., & Roberts, E. W. (2023) · Essays in Biochemistry · doi:10.1042/ebc20220244 · Cited by 1
The essential elements of adaptive immunity and their relevance to cancer immunology
Bullock, T. N. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87763-3.00016-2 · Cited by 1
Immunogenicity Threshold in Allogeneic Cells Impacts CTL Response to Nondominant Congenic Antigens
Rawat, K., Mara, A. B., King, W. T., Nnam, C. F., & Jakubzick, C. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300548 · Cited by 1
Edelson, B. T. (2022) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-87849-8_2 · Cited by 1
If it ain’t broke, break it: facilitating antigen cross-presentation
Rodríguez-Silvestre, P., & Kozik, P. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.02.007 · Cited by 1
Liu, A., Xia, Y., Li, W., Zhang, G., Liu, Y., Ye, S., Zhao, Z.-R., Yang, Y., Yu, J., Jia, Y., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-172495/v1 · Cited by 1
Interferon-induced lysosomal membrane permeabilization and death cause cDC1-deserts in tumorsPreprint
Aerakis, E., Chatzigeorgiou, A., Alvanou, M., Matthaiakaki-Panagiotaki, M., Angelidis, I., Koumadorakis, D. E., Γαλάρας, Α., Hatzis, P., Kerdidani, D., Makridakis, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.14.484263 · Cited by 2
Direct T-cell Presentation by cDC1: The Key Feature for Cancer Vaccine Success?
Hubert, M., Caux, C., & Valladeau‐Guilemond, J. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0473 · Cited by 1
Zindl, C. L., Wilson, C. G., Chadha, A. S., Cai, B., Harbour, S. N., Nagaoka-Kamata, Y., Hatton, R. D., Gao, M., Figge, D. A., & Weaver, C. T. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.03.539269 · Cited by 1
Hyperglycosylation of prosaposin in tumor DCs promotes immune escape in cancerPreprint
Sharma, P. L., Zhang, X., Ly, K., Kim, J. H., Wan, Q., Kim, J., Lou, M., Kain, L., Teyton, L., & Winau, F. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.14.545005 · Cited by 1
Stem-cell-like CD4+ T cells prey on MHC class II–negative tumors
Veatch, J. R., & Riddell, S. R. (2023) · Nature Immunology · doi:10.1038/s41590-023-01563-5 · Cited by 1
Paramitasari, K. A., & Ishida, Y. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.26.554968 · Cited by 1
Huang, S., Lai, Y., Liao, H.-T., Chang, C.-L., Ma, R.-Y., Chen, Y., Liou, Y.-H., Wu, Z., Wu, Y.-C., Liu, K., et al. (2024) · eLife · doi:10.7554/elife.99010 · Cited by 1
A cancer immunotherapy modality based on dendritic cell reprogramming in vivoPreprint
Ascic, E., Åkerström, F., Nair, M. S., Rosa, A., Kurochkin, I., Zimmermannová, O., Catena, X., Rotankova, N., Veser, C., Rudnik, M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.08.602356 · Cited by 1
Revitalizing systemic immune responses in advanced NSCLC using FLT3L and SBRTPreprint
Mathew, D., Ohri, N., Ngiow, S. F., Halmos, B., Wumesh, K. C., Garg, M. K., Levsky, J. M., Cheng, H., Gucalp, R. A., Bodner, W. R., et al. (2025) · medRxiv · doi:10.1101/2025.01.29.25321332 · Cited by 1
Roseth, I. A., Hatscher, L., Schiller, C., Johnstuen, H. S. S., Slørdahl, T., Hov, H., Schapiro, D., & Standal, T. (2025) · bioRxiv · doi:10.1101/2025.09.08.674473 · Cited by 1
Lareau, C. A., & Satpathy, A. T. (2020) · Nature Immunology · doi:10.1038/s41590-020-0796-0
Tumor MHCII immunity requires in situ antigen presentation by cancer-associated fibroblasts.Preprint
Kerdidani, D., Aerakis, E., Verrou, K., Stamoulis, P., Goudevenou, K., Prados, A., Tzaferis, C., Vamvakaris, I. N., Kaniaris, E., Vachlas, Κ., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-133564/v1
Lycke, N. Y., Arabpour, M., Lebrero‐Fernández, C., Schön, K., Strömberg, A., Börjesson, V., Lahl, K., Angeletti, D., & Agace, W. W. (2021) · Research Square · doi:10.21203/rs.3.rs-801483/v1
Fungal sugars boost vaccine protection
Lionakis, M. S. (2022) · Cell · doi:10.1016/j.cell.2022.01.020
Think global but act local: Tuning the dendritic cell response in cancer
Bravo‐Blas, A., Pirillo, C., Shergold, A. L., Andrusaite, A. T., & Roberts, E. W. (2022) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2022.106227
Metadata
- Authors
- Ferris, S. T., Durai, V., Wu, R., Theisen, D. J., Ward, J. P., Bern, M. D., Davidson, J. T., Bagadia, P., Liu, T., Briseño, C. G., Li, L., Gillanders, W. E., Wu, G. F., Yokoyama, W. M., Murphy, T. L., Schreiber, R. D., & Murphy, K. M.
- Affiliations
- Washington University in St. Louis (US)
- University of California, San Francisco (US)
- Barnes-Jewish Hospital (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Murphy, Kenneth M.
- ORCID
- Venue
- Nature
- Published
- 2020-08-12
- Volume
- 584
- Issue
- 7822
- Pages
- 624-629
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7469755
- OpenAlex
- W3048641542
- Cited by
- 611
- References
- 50
- Citations by year
- 2026: 112 · 2025: 105 · 2024: 112 · 2023: 127 · 2022: 76 · 2021: 67 · 2020: 12
- FWCI
- 24.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (UL1TR000448, UL1TR002345)
- National Cancer Institute (T32CA009573, R01CA190700, T32CA009621, R01CA248919, P30CA091842)
- National Institute of Allergy and Infectious Diseases (R01AI150297, R01AI129545, T32AI007163, R01AI162643)
- National Institute of Diabetes and Digestive and Kidney Diseases (F30DK108498, F30DK112466)
- National Institute of Neurological Disorders and Stroke (R01NS106289)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR073752)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- conventional type 1 dendritic cells, cDC1, CD4+ T cell priming, CD8+ T cell priming, MHC class II, MHC class I, cross-presentation, tumor rejection, antitumor immunity
- MeSH terms
- Animals, Histocompatibility Antigens Class II, Dendritic Cells, Female, Neoplasms, Signal Transduction, CD4-Positive T-Lymphocytes, Antigen Presentation, CD8-Positive T-Lymphocytes, CD40 Antigens, Cross-Priming, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
